DOWNLOAD THIS SLIDE KIT

BROWSE SLIDES

Design

Treatment regimens

• Co-formulated OBV/PTV/r ): 25/150/100 mg QD = 2 tablets ; SOF : 400 mg qd ; RBV : 1000 or 1200 mg/day (bid dosing) according to body weight (< or ≥ 75 kg )

Objective

• Primary endpoint: SVR₁₂ (HCV RNA < 25 IU/mL), with 2-sides 95% CI, by ITT [ *** The 2 OBV/PTV/r + SOF groups were pooled for analysis]

Baseline characteristics and SVR₁₂

* 1 relapse (no treatment-emergent substitutions), this patient had previously failed SOF + RBV
** 1 discontinuation of treatment on D8 due to an adverse event of influenza-like illness deemed unrelated to study drugs ; this patient did not achieve SVR₁₂

Adverse events and laboratory abnormalities

* Pneumonia on D26 unrelated to DAA ;
** 1 respir . tract infection on D33 ; 1 anemia on D28 , both unrelated to DAA;
***on D8 due to influenza - like symptoms unrelated to DAA ;
****on D78 due vertigo possibly related to DAA

Summary

• In patients with genotype 3 and no cirrhosis, high SVR rates were seen with 2D + SOF with or without RBV for 12 weeks
  • 100% without RBV and 91% with RBV (1 discontinuation for AE)
• In patients with genotype 3 and compensated cirrhosis, SVR₁₂ was 100% after 12 weeks of 2D + SOF + RBV
• In patients with genotype 2 and no cirrhosis, an 8-week regimen of 2D + SOF + RBV achieved an SVR₁₂ rate of 90 %
  • Shortening treatment duration to 6 weeks resulted in a high rate of relapse
• 2D + SOF ± RBV had a favorable safety profile consistent with previous studies
• Conclusion : 2D + SOF ± RBV may be a useful treatment option for patients with genotype 3 infection with or without cirrhosis
  • Limitation : small sample size